Do Youn Oh

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

<i>KRAS</i> mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han et al. · Molecular Carcinogenesis · 2010 · 127 citations

Medicine, Molecular Biology, Oncology +17

Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02

Kyung Hae Jung, Seock‐Ah Im, Joohyuk Sohn et al. · Journal of Clinical Oncology · 2013 · 84 citations

Medicine, Oncology, Breast Oncology +14

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

Jeeyun Lee, Kyung Hae Jung, Young Suk Park et al. · Cancer Chemotherapy and Pharmacology · 2009 · 77 citations · Full text

Medicine, Oncology, Pharmacology +12

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han et al. · Molecular Cancer Therapeutics · 2009 · 71 citations

Medicine, Oncology, Pharmacology +16